NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today reported financial results for the second quarter and first six-month period of fiscal year 2007. The Company reported a net loss of $5.5 million, or $.07 per share, for the second quarter of 2007 compared to a net loss of $5.7 million, or $.08 per share, for the second quarter of 2006. For the six months ended June 30, 2007, AVANT reported a net loss of $11.1 million, or $.15 per share, compared to a net loss of $8.6 million, or $.12 per share, for the six months ended June 30, 2006. The 2007 three and six month losses include one-time restructuring charges of $723,785. AVANT reported cash and cash equivalents of $26 million at June 30, 2007.
